scholarly journals Multimodal Deep Learning for Prognosis Prediction in Renal Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Stefan Schulz ◽  
Ann-Christin Woerl ◽  
Florian Jungmann ◽  
Christina Glasner ◽  
Philipp Stenzel ◽  
...  
Keyword(s):  
Deep Learning ◽  
Renal Cancer ◽  
Genomic Data ◽  
Medical Data ◽  
The Cancer Genome Atlas ◽  
Cell Renal Cell Carcinoma ◽  
Prognosis Prediction ◽  
Survival Status ◽  
Outcome Measurements ◽  
Mri Scans

BackgroundClear-cell renal cell carcinoma (ccRCC) is common and associated with substantial mortality. TNM stage and histopathological grading have been the sole determinants of a patient’s prognosis for decades and there are few prognostic biomarkers used in clinical routine. Management of ccRCC involves multiple disciplines such as urology, radiology, oncology, and pathology and each of these specialties generates highly complex medical data. Here, artificial intelligence (AI) could prove extremely powerful to extract meaningful information to benefit patients.ObjectiveIn the study, we developed and evaluated a multimodal deep learning model (MMDLM) for prognosis prediction in ccRCC.Design, Setting, and ParticipantsTwo mixed cohorts of non-metastatic and metastatic ccRCC patients were used: (1) The Cancer Genome Atlas cohort including 230 patients and (2) the Mainz cohort including 18 patients with ccRCC. For each of these patients, we trained the MMDLM on multiscale histopathological images, CT/MRI scans, and genomic data from whole exome sequencing.Outcome Measurements and Statistical AnalysisOutcome measurements included Harrell’s concordance index (C-index) and also various performance parameters for predicting the 5-year survival status (5YSS). Different visualization techniques were used to make our model more transparent.ResultsThe MMDLM showed great performance in predicting the prognosis of ccRCC patients with a mean C-index of 0.7791 and a mean accuracy of 83.43%. Training on a combination of data from different sources yielded significantly better results compared to when only one source was used. Furthermore, the MMDLM’s prediction was an independent prognostic factor outperforming other clinical parameters.InterpretationMultimodal deep learning can contribute to prognosis prediction in ccRCC and potentially help to improve the clinical management of this disease.Patient SummaryAn AI-based computer program can analyze various medical data (microscopic images, CT/MRI scans, and genomic data) simultaneously and thereby predict the survival time of patients with renal cancer.

scholarly journals Classification of Kidney Cancer Data Using Cost-Sensitive Hybrid Deep Learning Approach

Symmetry ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 154 ◽  
Author(s):  
Ho Sun Shon ◽  
Erdenebileg Batbaatar ◽  
Kyoung Ok Kim ◽  
Eun Jong Cha ◽  
Kyung-Ah Kim
Keyword(s):  
Gene Expression ◽  
Data Mining ◽  
Deep Learning ◽  
Kidney Cancer ◽  
Gene Expression Data ◽  
Genomic Data ◽  
Classification Model ◽  
Expression Data ◽  
Cancer Data ◽  
Prognosis Prediction

Recently, large-scale bioinformatics and genomic data have been generated using advanced biotechnology methods, thus increasing the importance of analyzing such data. Numerous data mining methods have been developed to process genomic data in the field of bioinformatics. We extracted significant genes for the prognosis prediction of 1157 patients using gene expression data from patients with kidney cancer. We then proposed an end-to-end, cost-sensitive hybrid deep learning (COST-HDL) approach with a cost-sensitive loss function for classification tasks on imbalanced kidney cancer data. Here, we combined the deep symmetric auto encoder; the decoder is symmetric to the encoder in terms of layer structure, with reconstruction loss for non-linear feature extraction and neural network with balanced classification loss for prognosis prediction to address data imbalance problems. Combined clinical data from patients with kidney cancer and gene data were used to determine the optimal classification model and estimate classification accuracy by sample type, primary diagnosis, tumor stage, and vital status as risk factors representing the state of patients. Experimental results showed that the COST-HDL approach was more efficient with gene expression data for kidney cancer prognosis than other conventional machine learning and data mining techniques. These results could be applied to extract features from gene biomarkers for prognosis prediction of kidney cancer and prevention and early diagnosis.

scholarly journals Comprehensive Analysis of Driver Genes in Personal Genomes of Clear Cell Renal Cell Carcinoma

2019 ◽  
Vol 18 ◽  
pp. 153303381983096 ◽  
Author(s):  
Jin Li ◽  
Liping Guo ◽  
Li Chai ◽  
Zisheng Ai
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Cancer Genome ◽  
The Cancer Genome Atlas ◽  
Driver Genes ◽  
Cell Renal Cell Carcinoma ◽  
Survival Status ◽  
Blue Module

Aim: To characterize personal driver genes in clear cell renal cell carcinoma independent of somatic mutation frequencies. Methods: Personal cancer driver genes were predicted by Integrated CAncer GEnome Score in 417 patients with clear cell renal cell carcinoma using 26 786 somatic mutations from The Cancer Genome Atlas, followed by an integrated investigation on personal driver genes. Results: A total of 233 personal driver genes were determined by Integrated CAncer GEnome Score. The coexpression network analysis found 5 coexpressed modules. The blue module was significantly negatively correlated with all 5 clinical features, including cancer stage, lymph node metastasis, distant metastasis, age, and survival status (death). CTNNB1, TGFBR2, KDR, FLT1, and INSR were the hub genes in the blue module. The expression of 79 personal driver genes was significantly associated with clinical outcomes of patients with clear cell renal cell carcinoma. Conclusions: The set of personal driver genes sheds insights into the tumorigenesis of clear cell renal cell carcinoma and paves the way for developing personalized medicine for clear cell renal cell carcinoma.

scholarly journals Development of Biologically Interpretable Multimodal Deep Learning Model for Cancer Prognosis Prediction

2021 ◽  
Author(s):  
Zarif L Azher ◽  
Louis J Vaickus ◽  
Lucas A Salas ◽  
Brock Christensen ◽  
Joshua Levy
Keyword(s):  
Deep Learning ◽  
Clinical Features ◽  
Preliminary Analysis ◽  
Clinical Information ◽  
The Cancer Genome Atlas ◽  
Cancer Prognosis ◽  
Biomedical Data ◽  
Cancer Subtypes ◽  
Prognosis Prediction ◽  
Modeling Approach

Robust cancer prognostication can enable more effective patient care and management, which may potentially improve health outcomes. Deep learning has proven to be a powerful tool to extract meaningful information from cancer patient data. In recent years it has displayed promise in quantifying prognostication by predicting patient risk. However, most current deep learning-based cancer prognosis prediction methods use only a single data source and miss out on learning from potentially rich relationships across modalities. Existing multimodal approaches are challenging to interpret in a biological or medical context, limiting real-world clinical integration as a trustworthy prognostic decision aid. Here, we developed a multimodal modeling approach that can integrate information from the central modalities of gene expression, DNA methylation, and histopathological imaging with clinical information for cancer prognosis prediction. Our multimodal modeling approach combines pathway and gene-based sparsely coded layers with patch-based graph convolutional networks to facilitate biological interpretation of the model results. We present a preliminary analysis that compares the potential applicability of combining all modalities to uni- or bi-modal approaches. Leveraging data from four cancer subtypes from the Cancer Genome Atlas, results demonstrate the encouraging performance of our multimodal approach (C-index=0.660 without clinical features; C-index=0.665 with clinical features) across four cancer subtypes versus unimodal approaches and existing state-of-the-art approaches. This work brings insight to the development of interpretable multimodal methods of applying AI to biomedical data and can potentially serve as a foundation for clinical implementations of such software. We plan to follow up this preliminary analysis with an in-depth exploration of factors to improve multimodal modeling approaches on an in-house dataset.

scholarly journals Integrating multi-platform genomic datasets for kidney renal clear cell carcinoma subtyping using stacked denoising autoencoders

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Tongjun Gu ◽  
Xiwu Zhao
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Genomic Data ◽  
Renal Clear Cell Carcinoma ◽  
The Cancer Genome Atlas ◽  
Low Grade ◽  
Cell Renal Cell Carcinoma ◽  
Unsupervised Deep Learning ◽  
Cancer Genome Atlas

Abstract Clear cell renal cell carcinoma (ccRCC) is highly heterogeneous and is the most lethal cancer of all urologic cancers. We developed an unsupervised deep learning method, stacked denoising autoencoders (SdA), by integrating multi-platform genomic data for subtyping ccRCC with the goal of assisting diagnosis, personalized treatments and prognosis. We successfully found two subtypes of ccRCC using five genomics datasets for Kidney Renal Clear Cell Carcinoma (KIRC) from The Cancer Genome Atlas (TCGA). Correlation analysis between the last reconstructed input and the original input data showed that all the five types of genomic data positively contribute to the identification of the subtypes. The first subtype of patients had significantly lower survival probability, higher grade on neoplasm histology and higher stage on pathology than the other subtype of patients. Furthermore, we identified a set of genes, proteins and miRNAs that were differential expressed (DE) between the two subtypes. The function annotation of the DE genes from pathway analysis matches the clinical features. Importantly, we applied the model learned from KIRC as a pre-trained model to two independent datasets from TCGA, Lung Adenocarcinoma (LUAD) dataset and Low Grade Glioma (LGG), and the model stratified the LUAD and LGG patients into clinical associated subtypes. The successful application of our method to independent groups of patients supports that the SdA method and the model learned from KIRC are effective on subtyping cancer patients and most likely can be used on other similar tasks. We supplied the source code and the models to assist similar studies at https://github.com/tjgu/cancer_subtyping.

Review of the Applications of Deep Learning in Bioinformatics

2021 ◽  
Vol 15 (8) ◽  
pp. 898-911
Author(s):  
Yongqing Zhang ◽  
Jianrong Yan ◽  
Siyu Chen ◽  
Meiqin Gong ◽  
Dongrui Gao ◽  
...  
Keyword(s):  
Deep Learning ◽  
Drug Discovery ◽  
Biomedical Imaging ◽  
State Of The Art ◽  
Black Box ◽  
Medical Data ◽  
Biological Data ◽  
High Dimensional ◽  
Biological Research ◽  
Process Data

Rapid advances in biological research over recent years have significantly enriched biological and medical data resources. Deep learning-based techniques have been successfully utilized to process data in this field, and they have exhibited state-of-the-art performances even on high-dimensional, nonstructural, and black-box biological data. The aim of the current study is to provide an overview of the deep learning-based techniques used in biology and medicine and their state-of-the-art applications. In particular, we introduce the fundamentals of deep learning and then review the success of applying such methods to bioinformatics, biomedical imaging, biomedicine, and drug discovery. We also discuss the challenges and limitations of this field, and outline possible directions for further research.

scholarly journals Explaining deep neural networks for knowledge discovery in electrocardiogram analysis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Steven A. Hicks ◽  
Jonas L. Isaksen ◽  
Vajira Thambawita ◽  
Jonas Ghouse ◽  
Gustav Ahlberg ◽  
...  
Keyword(s):  
Decision Making ◽  
Deep Learning ◽  
Deep Neural Networks ◽  
Clinical Decision Making ◽  
Medical Knowledge ◽  
Clinical Decision ◽  
Medical Data ◽  
Medical Doctors ◽  
Medical Tests ◽  
Deep Learning Model

AbstractDeep learning-based tools may annotate and interpret medical data more quickly, consistently, and accurately than medical doctors. However, as medical doctors are ultimately responsible for clinical decision-making, any deep learning-based prediction should be accompanied by an explanation that a human can understand. We present an approach called electrocardiogram gradient class activation map (ECGradCAM), which is used to generate attention maps and explain the reasoning behind deep learning-based decision-making in ECG analysis. Attention maps may be used in the clinic to aid diagnosis, discover new medical knowledge, and identify novel features and characteristics of medical tests. In this paper, we showcase how ECGradCAM attention maps can unmask how a novel deep learning model measures both amplitudes and intervals in 12-lead electrocardiograms, and we show an example of how attention maps may be used to develop novel ECG features.

scholarly journals Differential Expression of a Panel of Ten CNTN1-Associated Genes during Prostate Cancer Progression and the Predictive Properties of the Panel towards Prostate Cancer Relapse

Genes ◽  
2021 ◽  
Vol 12 (2) ◽  
pp. 257
Author(s):  
Yan Gu ◽  
Mathilda Jing Chow ◽  
Anil Kapoor ◽  
Xiaozeng Lin ◽  
Wenjuan Mei ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Differential Expression ◽  
Cancer Progression ◽  
Lncap Cell ◽  
Endocrine Resistance ◽  
Gene Panel ◽  
The Cancer Genome Atlas ◽  
Cancer Center ◽  
Poor Overall Survival ◽  
Cell Renal Cell Carcinoma

Contactin 1 (CNTN1) is a new oncogenic protein of prostate cancer (PC); its impact on PC remains incompletely understood. We observed CNTN1 upregulation in LNCaP cell-derived castration-resistant PCs (CRPC) and CNTN1-mediated enhancement of LNCaP cell proliferation. CNTN1 overexpression in LNCaP cells resulted in enrichment of the CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_3 gene set that facilitates endocrine resistance in breast cancer. The leading-edge (LE) genes (n = 10) of this enrichment consist of four genes with limited knowledge on PC and six genes novel to PC. These LE genes display differential expression during PC initiation, metastatic progression, and CRPC development, and they predict PC relapse following curative therapies at hazard ratio (HR) 2.72, 95% confidence interval (CI) 1.96–3.77, and p = 1.77 × 10−9 in The Cancer Genome Atlas (TCGA) PanCancer cohort (n = 492) and HR 2.72, 95% CI 1.84–4.01, and p = 4.99 × 10−7 in Memorial Sloan Kettering Cancer Center (MSKCC) cohort (n = 140). The LE gene panel classifies high-, moderate-, and low-risk of PC relapse in both cohorts. Additionally, the gene panel robustly predicts poor overall survival in clear cell renal cell carcinoma (ccRCC, p = 1.13 × 10−11), consistent with ccRCC and PC both being urogenital cancers. Collectively, we report multiple CNTN1-related genes relevant to PC and their biomarker values in predicting PC relapse.

scholarly journals Performance Comparison of Deep Learning Autoencoders for Cancer Subtype Detection Using Multi-Omics Data

Cancers ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 2013
Author(s):  
Edian F. Franco ◽  
Pratip Rana ◽  
Aline Cruz ◽  
Víctor V. Calderón ◽  
Vasco Azevedo ◽  
...  
Keyword(s):  
Deep Learning ◽  
Data Fusion ◽  
Similarity Measures ◽  
Research Problem ◽  
Optimal Number ◽  
Performance Comparison ◽  
The Cancer Genome Atlas ◽  
Cancer Type ◽  
Omics Data ◽  
Cancer Subtype

A heterogeneous disease such as cancer is activated through multiple pathways and different perturbations. Depending upon the activated pathway(s), the survival of the patients varies significantly and shows different efficacy to various drugs. Therefore, cancer subtype detection using genomics level data is a significant research problem. Subtype detection is often a complex problem, and in most cases, needs multi-omics data fusion to achieve accurate subtyping. Different data fusion and subtyping approaches have been proposed over the years, such as kernel-based fusion, matrix factorization, and deep learning autoencoders. In this paper, we compared the performance of different deep learning autoencoders for cancer subtype detection. We performed cancer subtype detection on four different cancer types from The Cancer Genome Atlas (TCGA) datasets using four autoencoder implementations. We also predicted the optimal number of subtypes in a cancer type using the silhouette score and found that the detected subtypes exhibit significant differences in survival profiles. Furthermore, we compared the effect of feature selection and similarity measures for subtype detection. For further evaluation, we used the Glioblastoma multiforme (GBM) dataset and identified the differentially expressed genes in each of the subtypes. The results obtained are consistent with other genomic studies and can be corroborated with the involved pathways and biological functions. Thus, it shows that the results from the autoencoders, obtained through the interaction of different datatypes of cancer, can be used for the prediction and characterization of patient subgroups and survival profiles.

Sign in / Sign up

Export Citation Format

Share Document